Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0165-54 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous June 30, 2024 In Use
71288-0101-10 71288-0101 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 1, 2017 Feb. 28, 2027 In Use
71288-0101-20 71288-0101 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 1, 2017 Feb. 28, 2027 In Use
72266-0125-01 72266-0125 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 15, 2019 In Use
72266-0125-10 72266-0125 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 2, 2019 In Use
72266-0126-01 72266-0126 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 15, 2019 In Use
72266-0126-10 72266-0126 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 2, 2019 In Use
00703-4502-04 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Dec. 1, 1991 In Use
00703-4502-84 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Aug. 17, 2015 March 31, 2021 In Use
00703-4502-94 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 9, 2015 July 31, 2020 In Use
00703-4502-93 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 4, 2024 In Use
25021-0259-50 25021-0259 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
25021-0259-51 25021-0259 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
46708-0813-50 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
46708-0813-63 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62332-0813-50 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62332-0813-63 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
00409-3414-01 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 2, 2006 In Use
00409-3414-11 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Aug. 26, 2024 In Use
00409-5255-25 00409-5255 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Nov. 14, 2022 In Use
72603-0320-01 72603-0320 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
72603-0420-01 72603-0420 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 5.0 mg/mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov. 14, 2022 In Use
16714-0572-01 16714-0572 Leuprolide acetate Leuprolide acetate 5.0 mg/ml Hormonal Therapy GnRH Agonist Subcutaneous Aug. 1, 2022 Sept. 30, 2024 In Use

Found 10,000 results in 11 millisecondsExport these results